MUC1 and prostate carcinoma: Atabi et al. showed aptamers that enhanced the storage of DOX in LNCaP cells (human prostate carcinoma cell line); Jing et al. constructed a double aptamer system that reduces human prostate cancer cell growth (LNCaP and PC3); Jeong et al. used mucin-1 aptamer (MUC-1) and DOX as treatment tools, on MCF-7 breast cancer cells and Sun et al. showed that the SL2B aptamer inhibits tumor growth in HT-29 cells (a human colorectal adenocarcinoma cell line) [101–104].